In this issue:
Increased risk of AD in children exposed prenatally to inorganic arsenic
Oral abrocitinib is safe and efficacious for adolescents with moderate-to-severe AD
British birth cohort study identifies novel AD subtype that has a delayed activity
Childhood AD linked to adverse mental health outcomes
Increased odds of AD and psoriasis in patients with chronic kidney disease
No genetic association between AD and depression or anxiety
Ocular surface disorders associated with dupilumab
Nurses play a critical role in therapeutic patient education
Proactive tacrolimus ointment therapy corrects skin lipid abnormalities
Network meta-analysis finds upadacitinib to be the most efficacious JAK inhibitor
Please login below to download this issue (PDF)